Seagen Inc represents a set of core values and a corporate philosophy that drive its operations. The company places great emphasis on advancing science to develop innovative targeted therapies for patients facing cancer. With a focus on precision medicine, Seagen Inc strives to provide therapies that address significant unmet medical needs. By collaborating with partners, the company aims to advance its mission to make a meaningful difference in the lives of cancer patients. Seagen Inc's dedication to scientific excellence, patient-centricity, and collaboration forms the foundation of its corporate philosophy and guides its pursuit of breakthrough treatments in the field of oncology.

Seagen Inc, a leading biotechnology company, is primarily present in multiple countries and regions across the world. With its headquarters in the United States, Seagen Inc has a significant presence in North America, including the United States and Canada. Additionally, the company extends its operations and reach to various European countries, such as Germany, France, Italy, Spain, and the United Kingdom. Seagen Inc also has a presence in Asia, with a focus on Japan. Through its global presence, Seagen Inc is dedicated to advancing innovative therapies and improving patient outcomes worldwide.

Seagen Inc, a renowned biotechnology company, has achieved numerous significant milestones. Notably, the company received the US Food and Drug Administration (FDA) approval for its groundbreaking antibody-drug conjugate, ADCETRIS®. This therapeutic innovation has revolutionized the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Seagen Inc has also successfully introduced EVOTEC and SGEN-001, expanding its product portfolio and advancing the fight against cancer. The company's commitment to research and development has resulted in crucial advancements and collaborations, consolidating its position as a leader in the biopharmaceutical industry. Seagen Inc's relentless pursuit of innovative solutions continues to make a substantial impact in transforming patients' lives.

Seagen Inc, formerly known as Seattle Genetics, is a biotechnology company based in Bothell, Washington. Established in 1997, Seagen focuses on the development and commercialization of innovative therapies for cancer treatment. The company has been at the forefront of antibody-drug conjugate (ADC) technology, which enables targeted delivery of potent drugs to cancer cells. Seagen's flagship product, ADCETRIS® (brentuximab vedotin), has gained significant recognition as a targeted therapy for Hodgkin lymphoma and certain types of non-Hodgkin lymphoma. With a commitment to advancing breakthrough therapies, Seagen continues to pave the way in the field of oncology.

The main competitors of Seagen Inc in the market include companies such as Genmab, AstraZeneca, and Roche.

Seagen Inc is primarily active in the biotechnology industry.

Seagen Inc, formerly known as Seattle Genetics, operates under a unique business model focused on biotechnology. The company specializes in developing and commercializing innovative antibody-based therapies to treat cancer. By harnessing the power of antibody-drug conjugates (ADCs), Seagen Inc aims to deliver targeted treatments directly to cancer cells while minimizing damage to healthy cells. This approach allows for more effective and precise treatment options, potentially improving patient outcomes. Seagen Inc's commitment to research, development, and collaboration with partners worldwide demonstrates their dedication to advancing cancer care and providing hope for patients globally.

P/E odnos Seagen iznosi -111,36.

KUV kompanije Seagen iznosi 12,73.

AlleAktien kvalitativni skor za Seagen je 6/10.

očekivana Seagen promet je 3,32 milijardi USD.

Dobit očekivana Seagen je -379,39 mil. USD.

Seagen Inc. is a biotechnology company specializing in the development of therapies for cancer and autoimmune diseases. The company was founded in 1998 and is headquartered in Seattle, USA. Seagen offers a wide range of products and services based on antibodies that can be used for the treatment of cancer and other serious diseases. The company operates in two main divisions: the commercial division and the clinical research and development division. The commercial division of Seagen currently distributes several approved products and therapies, including: - Adcetris: an antibody-drug conjugate (ADC) used for the treatment of lymphoma and Hodgkin's cancer. - Tukysa: an oral medication for the treatment of HER2-positive breast cancer. - Padcev: an ADC used for the treatment of bladder cancer. - Enfortumab Vedotin: an ADC used for the treatment of advanced urothelial carcinoma. - Seattle Genetics: a platform consisting of multiple antibody technologies used for the production of ADCs. Seagen's clinical research division is highly interested in developing new and innovative therapies for cancer and autoimmune diseases. One important area of research is new ADC products and antibody technologies that can help target cancer cells. Seagen pursues a comprehensive business model that includes the sale of new products and therapies, as well as collaborations with various pharmaceutical and biotech companies in the development of new technologies and therapies. The company has also entered into research collaborations with other companies and institutions to accelerate the discovery of new ADCs and other treatment options. In addition, Seagen also offers a range of services in the field of clinical studies, including planning, conducting, and analyzing studies. These services are offered to pharmaceutical and biotech companies developing their own products and technologies. Overall, Seagen aims to further expand its position as a leading provider of antibody-based therapies and products for cancer and autoimmune diseases. The company is committed to offering its customers and partners the best solutions and services to improve the treatment of patients worldwide. Answer: Seagen Inc. is a biotechnology company specializing in the development of therapies for cancer and autoimmune diseases. It offers a wide range of products and services for the treatment of cancer and other serious diseases, including antibody-drug conjugates (ADCs) such as Adcetris, Tukysa, Padcev, and Enfortumab Vedotin. Seagen is dedicated to developing new and innovative therapies, particularly in the field of ADC products and antibody technologies. The company operates in both commercial and clinical research divisions and collaborates with other organizations to accelerate the discovery of new treatment options. Additionally, Seagen provides services for clinical studies and aims to be a leading provider of antibody-based therapies worldwide.

Seagen isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Seagen trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Seagen je US81181C1045.

WKN od Seagen je 602322.

Oznaka za praćenje akcija kompanije Seagen je SGEN.

U poslednjih 12 meseci, Seagen je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Seagen će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Seagen trenutno iznosi .

Seagen isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Seagen je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Seagen se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Seagen od 5. 7. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 5. 7. 2024..

Isplata poslednje dividende izvršena je 5. 7. 2024..

U godini 2023 kompanija Seagen je isplatila 0 USD kao dividende.

Dividende od Seagen se isplaćuju u USD.